Identifying asymptomatic individuals at high risk of impending cognitive decline because of Alzheimer disease is crucial for successful prevention of dementia. Vascular risk and β-amyloid (Aβ) pathology commonly co-occur in older adults and are significant causes of cognitive impairment.
I dentifying asymptomatic individuals at high risk of impending cognitive decline because of Alzheimer disease (AD) is crucial to the success of clinical trials aimed at preventing dementia. The advent of in vivo measures of β-amyloid (Aβ) burden highlighted a preclinical phase of AD, 1,2 allowing for the identification of clinically normal individuals with objective evidence of AD pathology. However, a substantial portion of individuals who are amyloid positive do not show clear evidence of cognitive decline in available longitudinal follow-up data. [3] [4] [5] This is consistent with autopsy data indi-
cating that approximately 30% of clinically normal elderly individuals have signs of elevated Aβ burden on pathological examination. 6, 7 These findings have prompted the search for additional biomarkers that can be used with Aβ burden to identify individuals at maximal risk of cognitive decline. 4, 5, 8, 9 Most commonly, these additional biomarkers capture early signs of neurodegeneration, including alterations in cerebrospinal fluid tau, fludeoxyglucose F18-labeled (FDG) positron emission tomography (PET), and hippocampal volume. 8 Multiple studies have demonstrated that cardiovascular risk factors, such as hypertension and hyperlipidemia (which often occur together 10 ), are also risk factors for cognitive decline and AD. [11] [12] [13] [14] [15] Consistent with this, recent epidemiological data suggest that declining dementia incidence may be partially because of advances in the treatment of cardiovascular disease. 13, 16 Neuropathological studies indicate that vascular brain changes frequently co-occur with AD pathology in lateonset dementia and that vascular pathology may lower the threshold for cognitive impairment. [17] [18] [19] [20] [21] Neuroimaging studies examining the combined impact of Aβ burden and increased white matter hyperintensities (WMH; an imaging measure thought to reflect small vessel ischemic changes) and/or cerebral infarcts have generally demonstrated additive effects of Aβ burden and cerebrovascular pathology on cognition. [22] [23] [24] [25] [26] However, markers of cerebrovascular disease provided by conventional neuroimaging (eg, WMH, infarcts) may capture only a portion of total cerebrovascular disease burden, since many cerebrovascular changes are not well visualized on magnetic resonance imaging (MRI).
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The goal of the present study was to examine whether a well-validated, multivariable measure of vascular risk is associated with prospective cognitive decline in a large cohort of clinically normal elderly individuals, either additively or synergistically with Aβ burden. A secondary goal was to investigate whether vascular risk is associated with cognitive decline even after controlling for commonly used imaging biomarkers, including Aβ burden, FDG-PET, hippocampal volume, and WMH.
Methods

Participants
Participants were drawn from the Harvard Aging Brain Study (HABS), an ongoing longitudinal study of aging and preclinical AD. Participants provided written informed consent prior to study procedures, which used protocols approved by the Partners Healthcare institutional review board. Exclusionary criteria included a Hachinski score of 5 or more, history of stroke with residual deficits, and history of intracranial hemorrhage. At study entry, all participants had scores of 0 on the Clinical Dementia Rating, 32 11 or less on the Geriatric Depression Scale, 33 and 27 or more on the education-adjusted MiniMental State Examination, 34 and performed within educationadjusted norms on Logical Memory-delayed recall.
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Participants were required to have baseline imaging data from all modalities (MRI, FDG-PET, and Aβ-PET), baseline medical data to quantify vascular risk, and at least 1 follow-up neuropsychological visit. Apolipoprotein E (APOE) ε4 status was determined by the presence of at least 1 ε4 allele. Table 1 summarizes baseline participant characteristics.
Cardiovascular Disease Risk
Our primary measure of cardiovascular disease risk was the office-based Framingham Heart Study general cardiovascular disease (FHS-CVD) risk score. 36 The FHS-CVD risk score was calculated on baseline data and represents a weighted sum of age, sex, antihypertensive treatment (yes or no), systolic blood pressure (millimeters of mercury), body mass index, history of diabetes (yes or no), and current cigarette smoking status (yes or no). The FHS-CVD risk score provides a 10-year probability of future cardiovascular events (defined as coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and heart failure). In this sample, scores ranged from 4% to 88%, with higher scores representing greater risk of cardiovascular events. For stratified analyses and visualization purposes, participants were divided into high and low FHS-CVD risk groups based on a median split (at a FHS-CVD risk score of 29% 
Amyloid PET
Baseline Aβ burden was measured with carbon 11-labeled Pittsburgh compound-B (PiB) PET using previously described protocols. 38 Data were expressed as a distribution
Key Points
Question Is vascular risk associated with prospective cognitive decline in a cohort of clinically normal older adults, additively or synergistically with β-amyloid?
Findings In this study, Framingham and other vascular risk algorithms were associated with longitudinal cognitive decline, both alone and synergistically with β-amyloid burden. Vascular risk maintained a strong association with cognitive decline beyond that of commonly used imaging biomarkers, including β-amyloid, hippocampal volume, fludeoxyglucose F18-labeled positron emission tomography, and white matter hyperintensities.
Meaning Vascular risk may complement other imaging biomarkers in assessing risk of cognitive decline in older adults with preclinical Alzheimer disease. volume ratio using cerebellar gray as the reference region. A composite measure of cortical Aβ burden within frontal, lateral temporal and parietal, and retrosplenial cortices (FLR regions) was used to represent neocortical Aβ burden in statistical models. When needed, a Gaussian mixture modeling approach was used to classify participants as Aβ positive or Aβ negative using a previously published cutoff level of PiB FLR distribution volume ratio equal to 1.2.
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Fludeoxyglucose F18-Labeled PET Baseline fludeoxyglucose F18-labeled (FDG) PET imaging was performed using previously described protocols. 4 The mean FDG uptake was extracted from a previously published composite reflecting AD-vulnerable regions (lateral parietal, lateral inferior temporal, and posterior cingulate cortices) 39 and was normalized using a pons and vermis reference region.
Structural MRI
Baseline structural MRIs were collected on a 3-T Trio TIM MRI scanner (Siemens) using a 12-channel phased-array head coil according to previously described protocols. 
WMH Analysis
Baseline cortical WMH were assessed using fluid-attenuated inversion recovery MRI (repetition time = 6000 milliseconds; echo time = 454 milliseconds; inversion time = 2100 milliseconds; 1×1×1.5-mm voxels; 2 × acceleration). All WMH were identified using an automated algorithm 41 and previ- model entry. The presence or absence of microbleeds was investigated as a potential covariate in models that included Aβ burden, but was dropped from final models because of nonsignificant results. As indicated earlier, age and sex are incorporated into the FHS-CVD risk score. The primary analyses included age and sex as covariates; secondary analyses omitting age and sex as covariates yielded similar results (eTable 1 in the Supplement).
To investigate the associations of the FHS-CVD risk score and Aβ burden with prospective cognitive decline, we examined interactions of the FHS-CVD risk score with time and Aβ burden with time in a single model (model 1: PACC ෂ FHS-CVD × time + Aβ × time + covariates × time). Next, we added an interaction term between the FHS-CVD risk score, Aβ burden, and time to examine whether these 2 factors increase the likelihood of cognitive decline beyond their separate effects (ie, synergistic effect; model 2: PACC ෂ FHS-CVD × Aβ × time + covariates × time). To confirm the findings with the FHS-CVD risk score, a parallel set of analyses were computed using alternate measures of vascular risk (eTable 2 in the Supplement).
A secondary goal of the present study was to evaluate the unique influence of the FHS-CVD risk score on prospective cognitive decline while simultaneously controlling for commonly used imaging biomarkers, including Aβ burden, hippocampal volume, FDG-PET uptake, and WMH. To do so, we assessed the relative association of each biomarker with cognitive decline by including all biomarkers within a single model (model 3: PACC ෂ FHS-CVD × time + Aβ × time + hippocampal volume × time + FDG-PET × time + WMH × time + covariates × time). For comparison purposes, we also examined whether each of these biomarkers was associated with prospective PACC decline in separate models that controlled for Aβ burden. All models included lower-order effects. Nominal P values (< .05) were considered significant.
Results
Cross-sectional Associations of the FHS-CVD Risk Score, Imaging Biomarkers, and Cognition
Prior to longitudinal analyses, we examined the crosssectional associations between the FHS-CVD risk score and imaging biomarkers. After controlling for age and sex, a higher FHS-CVD risk score was associated with greater WMH (r = 0.21; P = .002) and lower FDG-PET uptake (r = −0.20; P = .002). There was no significant association of the FHS-CVD risk score with Aβ burden (r = −0.07; P = .30) or hippocampal volume (r = −0.08; P = .30; eFigure 1 in the Supplement). A secondary analysis omitting correction for age and sex strengthened the associations between the FHS-CVD risk score and WMH (r = 0.34; P < .001), hippocampal volume (r = −0.24; P < .001), and Aβ burden (r = −0.13; P = .06), although the association of the FHS-CVD risk score with Aβ burden was only marginally significant. The association of the FHS-CVD risk score with FDG-PET uptake was largely unchanged by the omission of age and sex as covariates (r = −0.18; P = .006; eFigure 1intheSupplement).
We next examined independent and interactive associations of the FHS-CVD risk score and Aβ burden with baseline cognition, covarying for age, sex, years of education, and APOE ε4 status. The FHS-CVD risk score was marginally associated with baseline cognition (β = −0.09; 95% CI, −0.20 to 0.01; P = .09), whereas Aβ burden was not (β = 0.01; 95% CI, −0.07 to 0.09; P = .87). There was no interaction between the FHS-CVD risk score and Aβ burden with baseline cognition (β = 0.03; 95% CI, −0.06 to 0.12; P =.48).
Associations of the FHS-CVD Risk Score and Aβ Burden With Prospective Cognitive Decline
Of primary interest was whether an elevated FHS-CVD risk score and higher Aβ burden were additive or synergistic in their associations with faster cognitive decline (model 1). Both a higher FHS-CVD risk score and higher Aβ burden were associated with faster PACC decline ( Table 2) . Possible synergistic effects were tested in a separate model that included the interaction between the FHS-CVD risk score, Aβ burden, and time (model 2). The presence of a significant interaction term suggests that an elevated FHS-CVD risk score together with a higher Aβ burden increases the likelihood of cognitive decline beyond their separable effects ( Figure 1 and Table 2 ; eFigure 2 in the Supplement). Participant APOE ε4 status was not associated with cognitive decline in any of the above models. Alternate vascular risk scores (the lipid-based FHS-CVD risk score, Revised Framingham Stroke Risk Profile, and QRISK2-2016) in place of FHS-CVD risk score yielded similar results with respect to the main and Aβ interactive associations with prospective cognitive decline (eTable 2 in the Supplement).
We next examined whether a higher FHS-CVD risk score was associated with cognitive decline in both Aβ-positive and Aβ-negative groups. The FHS-CVD risk score was associated with decline in both groups, but the effect was larger in the Aβ-positive group (Aβ-positive: β = −0.101; 95% CI, −0.184 to −0.018; P = .02; Aβ-negative: β = −0.03; 95% CI, −0.055 to Using this grouping, we observed a significant association of group with prospective cognitive decline after adjusting for covariates (β = 0.042; 95% CI, 0.013 to 0.070; P = .005; Figure 1 ). Post hoc analyses revealed significantly faster cognitive decline in the group that was Aβ-positive with a high FHS-CVD risk score compared with all other groups (vs Aβ-positive with a low FHS-CVD risk score: β = 0.10; 95% CI, 0.02 to 0.19; P = .02; Aβ-negative with a high FHS-CVD risk score: β = 0.12; 95% CI, 0.05 to 0.19; P = .001; Aβ-negative with a low FHS-CVD risk score: β = 0.21; 95% CI, 0.14 to 0.29; P < .001). The group that was Aβ-negative with a low FHS-CVD risk score demonstrated significantly improved performance over time compared with all other groups, likely indicating a practice effect (vs Aβ-positive with a low FHS-CVD risk score: β = −0.11; 95% CI, −0.16, −0.06, P < .001; Aβ-negative with a high FHS-CVD risk score: β = −0.08; 95% CI, −0.13 to −0.04; P < .001; Aβ-positive with a high FHS-CVD risk score: β = −0.20; 95% CI, −0.25 to −0.14; P < .001). There was no difference between the cognitive trajectories of the group that was Aβ-positive with a low FHS-CVD risk score and the group that was Aβ-negative with a high FHS-CVD risk score.
Association of the FHS-CVD Risk Score With Prospective Cognitive Decline, Controlling for Imaging Biomarkers
A secondary goal was to examine whether the FHS-CVD risk score was associated with PACC decline after adjusting for imaging biomarkers, including Aβ burden, hippocampal volume, FDG-PET uptake, and WMH (model 3). As summarized in Table 2 and Figure 2 , the FHS-CVD risk score remained strongly associated with PACC decline even after including these imaging biomarkers in the model. Hippocampal volume and Aβ burden were also significantly associated with cognitive decline in model 3. When each biomarker was considered in a separate model that controlled for Aβ burden, all biomarkers were significantly associated with PACC decline, with the exception of WMH (eTable 3 in the Supplement).
Discussion
We examined whether a well-validated summary measure of vascular risk was associated with prospective cognitive decline in clinically normal elderly, either additively or synergistically with Aβ burden. The FHS-CVD risk score and Aβ burden each was associated with longitudinal cognitive decline when entered together into a single model. These findings underscore the importance of both vascular risk and Aβ burden to cognitive decline in clinically normal older adults. Additionally, we observed a robust interaction between the FHS-CVD risk score and Aβ burden in association with prospective cognitive decline, whereby individuals with both higher vascular risk and higher Aβ burden showed the steepest decline in cognition on longitudinal follow-up. Supplemental analyses using alternate vascular risk algorithms showed a similar pattern of results. Finally, the FHS-CVD risk score remained strongly associated with cognitive decline after accounting for commonly used imaging biomarkers, suggesting that vascular risk may complement existing biomarkers of neurodegeneration and molecular pathology in assessing risk of cognitive decline. Notably, we did not observe a clear association of the baseline FHS-CVD risk score with Aβ burden in our study sample. While we did not observe a positive association of the FHS-CVD risk score with Aβ burden at baseline, our results indicated a synergism between these 2 factors in promoting cognitive decline. This observed synergy is consistent with neuropathological studies, suggesting that the presence of substantial cerebrovascular disease may lower the threshold at which AD pathology leads to cognitive decline. [17] [18] [19] Some prior studies examining the combined impact of Aβ burden and WMH and/or cerebral infarcts on cognition in clinically normal older adults have found additive rather than synergistic effects. 22,23 One possible explanation for this difference is that the FHS-CVD risk score may capture aspects of vascular burden that are not well represented by WMH and/or infarcts. This idea is consistent with the relatively weak association of the FHS-CVD risk score with WMH in the current sample, and the observation that the FHS-CVD risk score remained strongly associated with cognitive decline even after adjusting for WMH in statistical models. Prior studies suggest that many cerebrovascular changes observed at autopsy are not well visualized on MRI, including arteriosclerosis, microinfarcts, and disruptions of the blood brain barrier. [27] [28] [29] [30] [31] Further work is needed to examine potential interactions between vascular pathology and Aβ burden using more comprehensive markers of cerebrovascular disease, as such measures may better reflect the results seen here with multivariable vascular risk scores.
Limitations
The present results are best understood in the context of the study sample composition. Because HABS excludes participants with unstable hypertension and uncontrolled diabetes, as well as symptomatic stroke or intracranial hemorrhage, the higher range of vascular risk may be underrepresented in the study sample. This consideration affects the interpretation of our stratified models, because the median level of vascular risk within the general population is likely higher than the median level of vascular risk within the HABS sample. Similarly, individuals with both high vascular risk and high Aβ burden are likely underrepresented in our sample because they are more likely to be cognitively impaired and thus excluded from study participation. However, our results do suggest that even relatively modest levels of vascular risk can interact with Aβ burden to hasten cognitive decline. Another potential limitation is that the age range in HABS (maximum age of 89 years) extends beyond the age range of the sample used to initially validate the FHS-CVD risk score (which was 30 to 74 years), 36 perhaps affecting the estimation of vascular risk in older participants. It remains an open question whether or not to separately control for age and sex when using multivariable vascular risk algorithms, such as the FHS-CVD risk score, because these demographic variables are incorporated into these risk prediction models. As a practical matter, we observed that there was little difference between models that included age and sex as separate covariates (as in the main text) from those that did not (eTable 1 in the Supplement). Finally, most HABS participants have at least some advanced education and may have substantial cognitive reserve, factors that may affect the generalizability of these findings.
Conclusions
In summary, our results suggest that vascular risk has a potent association with longitudinal cognitive decline, both alone and synergistically with Aβ burden in clinically normal older adults. Vascular risk remained strongly associated with prospective cognitive decline even after accounting for commonly used imaging biomarkers, suggesting that measures of vascular risk may complement imaging biomarkers in assessing risk of cognitive decline in clinically normal elderly. Finally, the observed synergy between vascular risk and Aβ burden in promoting cognitive decline is consistent with neuropathological findings suggesting that the presence of vascular pathology may shorten the preclinical phase of AD 17-21 and also with epidemiological studies suggesting that improved cardiovascular health may be partially responsible for declining dementia incidence over the past 30 years. 16 Together, these results bolster the scientific rationale for aggressively targeting vascular risk factors, either alone or in concert with anti-amyloid therapies, as a potential approach to delay cognitive decline in older adults. 
eMethods. Alternate measures of vascular risk
Several multivariable risk assessment algorithms have been developed to estimate risk of cardiovascular disease. In the main paper, we quantified vascular risk using the office-based Framingham Heart Study general cardiovascular disease (FHS-CVD) risk score. 1 To confirm these findings, we examined alternate measures of vascular risk, including the lipid-based FHS-CVD risk score (which replaces body mass index with cholesterol), the Revised Framingham Stroke Risk Profile (FSRP), and the QRISK2-2016. All risk prediction models are scaled to predict a 10-year risk of a cardiovascular event or stroke. A brief description of each risk prediction model is provided below.
The lipid-based FHS-CVD risk score
The lipid-based FHS-CVD risk score predicts an individual's 10-year risk of a cardiovascular event.
1 The score incorporates the following variables into its risk prediction algorithm: age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure (mmHg), use of antihypertensive medication (yes/no), current smoking status (yes/no), and history of diabetes (yes/no). Thirty-four participants were missing cholesterol data; therefore only 189 participants were included in analyses using this algorithm. The mean lipid-based FHS-CVD score in our sample was 24.1 (SD = 15.1). There was a high correlation between the lipid-based FHS-CVD risk score and the office-based FHS-CVD risk score (which uses body mass index in place of cholesterol) in our sample (r = 0.90, p < .001).
The Revised Framingham Stroke Risk Profile
The Revised Framingham Stroke Risk Profile (FSRP) predicts an individual's 10-year risk of stroke. 2 The score incorporates the following variables into its risk prediction algorithm: age, sex, current smoking status (yes/no), atrial fibrillation (yes/no), history of diabetes (yes/no), use of hypertension medication (yes/no), and systolic blood pressure (mmHg). The mean FSRP in our sample was 10.8 (SD = 9.1). There was a significant correlation between the FSRP and the office-based FHS-CVD risk score in our sample (r = 0.60, p < .001).
QRISK2-2016
The QRISK2-2016 risk score predicts an individual's 10-year risk of a cardiovascular event. The algorithm is based on a large primary care database in England and Wales. All scores were entered manually into the QRISK website calculator (https://qrisk.org/2016/) using all available data. The QRISK risk prediction model incorporates the following variables: age, sex, ethnicity, smoking status (non-smoker, ex-smoker, light smoker, moderate smoker, heavy smoker), diabetes status (none, type I, type II), chronic kidney disease (stage 4 or 5), atrial fibrillation (yes/no), use of antihypertensive medication (yes/no), rheumatoid arthritis (yes/no), total cholesterol/high-density lipoprotein ratio, systolic blood pressure (mmHg), and body mass index. Smoking status was entered as non-smoker or moderate smoker given that smoking data in our sample was collected as yes/no. The calculator only provides scores for individuals up to the age of 84, therefore participants older than 84 were entered as if they were 84 years old. Family history information (i.e., chronic kidney disease or angina or heart attack in a first degree relative) fields were left blank, as this information was not uniformly gathered in the Harvard Aging Brain Study. Cholesterol fields were left blank in individuals with missing lipid data. Postcode fields were left blank, since this was not applicable. The mean QRISK2-2016 in our sample was 25.6 (SD = 12.9). There was a significant correlation between the QRISK2-2016 and the office-based FHS-CVD risk score in our sample (r = 0.75, p < .001).
Statistical Analyses
To confirm the patterns seen with the office-based FHS-CVD risk score reported in the main text, we repeated the main analyses presented in the paper with the lipid-based FHS-CVD risk score, the FSRP, and the QRISK2-2016.
Results
As summarized in eTable 2, we replicated the results presented in the main paper with each of the three risk prediction models. All models demonstrated that vascular risk predicted longitudinal cognitive decline alone and in concert with Aβ burden. 
